FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-? inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
Stock Information for Eton Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.